China's BioDlink International HY revenue falls

By Reuters News


Overview

  • China CDMO provider's half-year revenue fell to RMB 246 bln

  • Company expanded CDMO operations and invested in R&D during the reporting period

  • WuXi XDC completed acquisition, bringing new leadership and strategic direction


Outlook

  • Company did not provide specific financial guidance in the interim report


Result Drivers

  • CDMO EXPANSION - Co said accelerated expansion of CDMO operations contributed to results

  • PRODUCT PRESSURE – Product revenue fell 89% yr/yr to RMB45 mln, mainly due to intensified market competition and volume-based procurement

  • R&D RESOURCE REALLOCATION – R&D expenses fell 25% yr/yr to RMB27 mln as product pipelines were streamlined and resources shifted to CDMO development


Company press release: Full Story


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

RMB 246.01 mln


Analyst Coverage

  • The one available analyst rating on the shares is "strong buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for BioDlink International Co Ltd is HK$4.40, about 17.3% above its September 28 closing price of HK$3.75


Reuters Recommended Reads

  • Sept 28 - China's Fudan Microelectronics HY revenue, profit rise

  • Sept 29 - Novo Nordisk to license GLP-1 drug from China's Hengrui in $2.6 billion deal

  • Sept 28 - France's Inventiva H1 net loss narrows


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


Press Release https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0929/2026092901031.pdf

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.